Last reviewed · How we verify
Imovane (ZOPICLONE)
Imovane (Zopiclone) is a small molecule drug developed by Sunovion Pharmas Inc, targeting the GABA A receptor alpha-5/beta-2/gamma-2. It is a non-benzodiazepine hypnotic agent, classified as a zopiclone, approved by the FDA in 2004 for the treatment of insomnia. Imovane is still owned by Sunovion Pharmas Inc and is used to help individuals fall asleep and stay asleep. Key safety considerations include its potential for dependence and withdrawal symptoms. Imovane has a half-life of 5.2 hours.
At a glance
| Generic name | ZOPICLONE |
|---|---|
| Sponsor | Sunovion Pharms Inc |
| Drug class | zopiclone |
| Target | GABA A receptor alpha-5/beta-2/gamma-2 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 2004 |
Approved indications
- Insomnia
Common side effects
Key clinical trials
- National Adaptive Trial for PTSD Related Insomnia (PHASE3)
- A Cohort Study on Increasing Blood Pressure Benefits in Sleep Apnea Patients After CPAP Treatment
- Continuous Positive Airway Pressure, Arousability and Links to Mechanisms in Obstructive Sleep Apnea (PHASE3)
- Endotype-Targeted Therapy to Rescue OSA Patients Struggling With CPAP Adherence (TOP-CPAP) (PHASE2)
- Effectiveness of Combining Behavioral and Pharmacologic Therapy for Complex Insomnia in Veterans With PTSD (PHASE4)
- Endotypic Traits and Obstructive Sleep Apnea Surgery (PHASE2)
- Impact of Eszopiclone on Blood Pressure in Patients With Insomnia and Hypertension (PRYSMA-HTN) (PHASE4)
- Grain Moxibustion Treatment on Insomnia: a Randomized Controlled Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Imovane CI brief — competitive landscape report
- Imovane updates RSS · CI watch RSS
- Sunovion Pharms Inc portfolio CI